FDA Orphan Drug Requests Could Start To Rely More On Non-Profitability Criteria

The Food & Drug Administration may start to see more requests for orphan drug designation based on a little-used criterion under the Orphan Drug Act: a drug that is not expected to recoup the development costs before the end of the seven-year exclusivity period.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet